GlassScriptPhysician profile
Nicole Abel
NPI 1073142022
$1,812.91
in general payments reported to CMS, 2019-2025
17 companies · $49.12 in 2025
The $49.12 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $28.29 · 2023: $168 · 2024: $1,567 · 2025: $49.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,784.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $303.23 | 2023-2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $273.87 | 2024 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $245.55 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $215.55 | 2022-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $182.45 | 2023-2024 | Ubrelvy |
| Abbott Laboratories | $177.17 | 2024 | Freestyle Libre 3 |
| Pfizer INC. | $175.06 | 2023-2024 | |
| Exact Sciences Corporation | $38.37 | 2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.14 | 2024 | Jardiance |
| Phathom Pharmaceuticals, INC. | $34.77 | 2024 | Voquezna |
| Antares Pharma, INC. | $34.03 | 2024 | Xyosted |
| Genentech USA, INC. | $20.55 | 2025 | Ocrevus Zunovo |
| Merck Sharp & Dohme LLC | $17.62 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Glaxosmithkline, LLC. | $14.91 | 2025 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $14.55 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $14.23 | 2024 | Onzetra Xsail, Contrave |
| Sanofi-Aventis U.S. LLC | $13.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Abel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.